Anat Stemmer-Rachamimov, M.D.
This page shows the publications co-authored by Anat Stemmer-Rachamimov and Casey Maguire.
The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. Hum Gene Ther. 2022 01; 33(1-2):61-75.
Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. J Neurooncol. 2018 Sep; 139(2):293-305.
Preventing growth of brain tumors by creating a zone of resistance. Mol Ther. 2008 Oct; 16(10):1695-702.
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Sci Adv. 2021 Jan; 7(2).
Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Mol Ther Methods Clin Dev. 2019 Dec 13; 15:18-26.
Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro Oncol. 2019 07 11; 21(7):854-866.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.